Ropivacaine (mixed presentations): Hospital supply issue
This issue affects five presentations of Ropivacaine Kabi.
Affected product
Because of constraints in the manufacturing plant, Fresenius Kabi has limited supplies of some ropivacaine presentations. Shipments continue to arrive, however supply continues to be constrained. The most affected products, as at 5 February 2026, are as follows.
| Presentation | Pharmacode | Supply status | Next shipment |
|---|---|---|---|
| 2 mg/ml, 200 ml bag | 2479117 | Limited stock available | end February 2026 |
| 2 mg/ml, 20 ml ampoule | 2478714 | Stock available | mid-February 2026 |
| 7.5 mg/ml, 10 ml ampoule | 2478722 | Limited stock available | February, March and April 2026 |
| 7.5 mg/ml, 20 ml ampoule | 2478730 | Stock available |
Late February 2026 |
| 10 mg/ml, 10 ml ampoule | 2478749 | Stock available | mid-February 2026 |
| 10 mg/ml, 20 ml ampoule | 2478765 | Stock Available |
mid-February 2026 |
Other presentations remain available.
Ropivacaine listings in the HML(external link)
Shipments
The dates given in the table are for when stock arrives in New Zealand. The product will still need to clear standard quality control processes before being released. Fresenius Kabi is working to make that process as quick as possible.
The next shipments listed will not resolve the issue completely. We are continuing to monitor the situation and will keep this page up to date.
Who to contact
If you have questions about this issue, email enquiry@pharmac.govt.nz
Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.
Sign up to our email list for regular emails about supply issues and more(external link)
Pharmac is a government agency. We do not sell medicines or related products.